- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.07. | Polyrizon Advances on Test Results | 1 | Baystreet.ca | ||
| 02.07. | Polyrizon: Positive Studiendaten zur Biokompatibilität beflügeln die Aktie | - | Investing.com Deutsch | ||
| 02.07. | Polyrizon completes biocompatibility tests for allergy nasal spray | 1 | Investing.com | ||
| 02.07. | Polyrizon Ltd.: Polyrizon Announces Successful Results for NASARIX Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial | 255 | GlobeNewswire (Europe) | Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 29.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 29.06. | Polyrizon erhält Zulassung für klinische Studie zu Allergen-Nasenspray | - | Investing.com Deutsch | ||
| 29.06. | Polyrizon Ltd.: Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial | 263 | GlobeNewswire (Europe) | Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 17.06. | Polyrizon receives U.S. patent publication notice for nasal drug delivery platform | 4 | Seeking Alpha | ||
| 17.06. | Polyrizon Ltd.: Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform | 389 | GlobeNewswire (Europe) | Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 15.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.06. | Klinische Studie zu Allergieblocker treibt Polyrizon Aktie an | 2 | Investing.com Deutsch | ||
| 15.06. | Polyrizon initiates nasal residence time study for allergy blocker | 2 | Investing.com | ||
| 15.06. | Polyrizon Ltd.: Polyrizon Advances NASARIX Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway | 1 | GlobeNewswire (USA) | ||
| 10.06. | Polyrizon Marches on European Patent | - | Baystreet.ca | ||
| 10.06. | Polyrizon receives European patent application publication | 1 | Investing.com | ||
| 10.06. | Polyrizon Ltd.: Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology | 377 | GlobeNewswire (Europe) | Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 08.06. | Polyrizon signs two more U.S. sites for allergy trial | 1 | Investing.com | ||
| 08.06. | Polyrizon Ltd.: Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX Trial | 1 | GlobeNewswire (USA) | ||
| 05.06. | Polyrizon verlängert Exklusivitätsfrist für Übernahmegespräche mit Arrow Aviation | 1 | Investing.com Deutsch |
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,290 | -0,98 % | Qiagen-Aktie: Jetzt auf Fünfmonatshoch - lohnt sich der Einstieg? | Qiagen-Aktien legen heute kräftig zu. An der Frankfurter Börse kletterten die Papiere des Diagnostikspezialisten um 4 Prozent nach oben und markierten damit den höchsten Stand seit fünf Monaten. Der... ► Artikel lesen | |
| NOVAVAX | 6,950 | -0,14 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,640 | +1,69 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| BIOXXMED | 1,000 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| OCUGEN | 1,162 | -0,17 % | Ocugen präsentiert spätphasige Gentherapie-Strategie für Augenerkrankungen | ||
| INOVIO PHARMACEUTICALS | 0,920 | -1,92 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,575 | -11,85 % | COSCIENS Biopharma Inc. Reports Q2 2026 Results | TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) ("COSCIENS" or the "Company") today reported its financial and operating results for the second... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,296 | -0,34 % | NurExone Biologic: Wie Exosomen den Sehnerv wieder zum Wachsen bringen könnten | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,024 | +2,56 % | PacBio im Umbruch: Klinisches Wachstum kompensiert kurzfristige Belastungen | ||
| REDHILL BIOPHARMA | 0,580 | -0,70 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 1,090 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 | King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,321 | -7,90 % | Onco-Innovations Limited: Onco-Innovations Advances ONC010 Polymer Development with Identification of Non-Tin Catalyst and Provides Integrated Update | ||
| NOVOCURE | 14,565 | 0,00 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,500 | -2,30 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,020 (+0,18 %) liegt der Kurs bei 11,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.